Unmasking Tardive Dyskinesia: Recognizing, Preventing, and Treating Involuntary Movements

What is Tardive Dyskinesia?

Tardive Dyskinesia (TD) is a neurological disorder characterized by involuntary, repetitive movements, primarily affecting the face, tongue, and limbs. These movements can include grimacing, tongue movements, lip smacking, and rapid eye blinking. In some cases, the condition may also cause rapid movements of the arms, legs, and trunk.

Causes of Tardive Dyskinesia

TD most commonly arises as a side effect of long-term use of antipsychotic medications, particularly first-generation antipsychotics (also known as typical antipsychotics) such as haloperidol and chlorpromazine. These medications are used to treat psychiatric disorders like schizophrenia and bipolar disorder. Second-generation antipsychotics (atypical antipsychotics) are also associated with TD, though the risk is generally lower compared to first-generation drugs .

The exact mechanism behind TD is not fully understood, but it is believed that prolonged exposure to antipsychotic medications leads to alterations in the brain's dopamine receptors. Dopamine is a neurotransmitter involved in controlling movement and coordination. The chronic blockade of dopamine receptors by these medications may lead to an unregulation and hypersensitivity of these receptors, causing the abnormal movements seen in TD .

Symptoms of Tardive Dyskinesia

The symptoms of TD can vary widely in severity and may include:

• Facial Movements: Grimacing, lip smacking, tongue protrusion, and chewing movements.
• Limb Movements: Rapid, jerky movements of the arms, legs, and fingers.
• Trunk Movements: Twisting, squirming, or rocking motions.
• Eye Movements: Rapid blinking or involuntary eye movements (tardive oculogyric crisis).

These symptoms can significantly impact a person's quality of life, leading to social embarrassment, difficulty eating, speaking, and performing daily activities .

Diagnosis and Treatment

Diagnosing TD involves a thorough clinical evaluation, including a detailed medical history and medication review. Healthcare providers use standardized rating scales, such as the Abnormal Involuntary Movement Scale (AIMS), to assess the severity and progression of symptoms .

Treatment Options

Management of TD primarily focuses on minimizing symptoms and improving the patient's quality of life. Treatment strategies include:

1. Medication Adjustments: Reducing the dose or discontinuing the offending antipsychotic medication, if possible. Switching to a different antipsychotic with a lower risk of TD may also be considered.
2. Medications for TD: Several medications have been approved to treat TD, including:
   • Valbenazine (Ingrezza): A vesicular monoamine transporter 2 (VMAT2) inhibitor that helps reduce abnormal movements.
   • Deutetrabenazine (Austedo): Another VMAT2 inhibitor that works similarly to valbenazine .
3. Supportive Therapies: Physical therapy, occupational therapy, and speech therapy can help manage symptoms and improve daily functioning.
4. Lifestyle Modifications: Stress reduction techniques, a balanced diet, and regular exercise can support overall well-being and may help manage symptoms.

Tardive Dyskinesia is a challenging condition often associated with long-term use of antipsychotic medications. Understanding its symptoms, causes, and treatment options is crucial for effective management. If you or a loved one is experiencing symptoms of TD, it is important to consult a healthcare provider for a comprehensive evaluation and personalized treatment plan. It is also important to never stop taking your prescribed medication unless you speak to your doctor first.

References

1. U.S. National Library of Medicine. (2021). Tardive Dyskinesia. MedlinePlus. Retrieved from MedlinePlus
2. American Psychiatric Association. (2020). Practice Guideline for the Treatment of Patients with Schizophrenia. Retrieved from APA
3. Kane, J. M., & Correll, C. U. (2010). Past and present progress in the pharmacologic treatment of schizophrenia. Journal of Clinical Psychiatry, 71(9), 1115-1124.
4. Cloud, L. J., & Zutshi, D. (2012). Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder. Neuropsychiatric Disease and Treatment, 8, 135-148.
5. Guy, W. (1976). Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health.
6. Citrome, L. (2017). Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 71(7), e12964.
7. Fernandez, H. H., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., & Jankovic, J. (2017). Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology, 88(20), 2003-2010.